期刊文献+

药师干预儿科重点监控药品磷酸肌酸钠效果评价

Effect Evaluation of Pharmacists ’ Intervention on Key Monitoring of Creatine Phosphate Sodium in Pediatrics
下载PDF
导出
摘要 目的:制定并实施针对儿科重点监控药品磷酸肌酸钠的干预方案,促进其在临床的合理使用。方法:收集我院2020年11月至2021年4月使用磷酸肌酸钠患儿的病历,抽取300份进行专项点评。针对点评中发现的问题,通过培训与宣教、加强医嘱审核与用药监护、建立药品领用审批流程进行干预。之后以同样方法抽取2021年5-10月病历300份,对比分析干预前后磷酸肌酸钠的用药情况。结果:药师干预后,全院磷酸肌酸钠的使用率由15.96%下降至4.84%,用药金额从351.65万元下降至134.44万元。35个住院科室中有33个部门的用药金额出现下降,其中16个科室未再使用该药品。磷酸肌酸钠用药合理率由62.33%提高至93.67%(P<0.05)。结论:培训与宣教、加强医嘱审核与用药监护、建立药品领用审批流程等举措能够促进磷酸肌酸钠的合理使用。 Objective:To formulate and implement the intervention regimen for the key monitoring of creatine phosphate sodium in pediatrics,so as to promote the rational use in clinic.Methods:Medical orders of pediatric patients received creatine phosphate sodium in our hospital from Nov.2020 to Apr.2021 were collected,and 300 medical orders were selected for special review.In view of the problems found in the review,intervention was carried out through training and education,strengthening the review of medical orders and medication monitoring,and establishing the approval process for drug use.And 300 medical orders from May to Oct.2021 were selected by the same method.The use of creatine phosphate sodium before and after intervention was compared and analyzed.Results:After pharmacists’intervention,the utilization rate of creatine phosphate sodium decreased from 15.96%to 4.84%,and the consumption sum decreased from 3.516,5 million yuan to 1.344,4 million yuan.Of the 35 inpatient departments,33 departments showed a decrease in the consumption sum,of which 16 departments did not use the drug anymore.The rational utilization rate of creatine phosphate sodium increased from 62.33%to 93.67%,the difference was statistically significant(P<0.05).Conclusion:The rational use of creatine phosphate sodium can be promoted through training and education,strengthening the review of medical orders and medication monitoring,and establishing the approval process for drug use.
作者 关玮伟 李英 史强 杜朝阳 魏京海 Guan Weiwei;Li Ying;Shi Qiang;Du Zhaoyang;Wei Jinghai(National Center for Children’s Health,Beijing Children’s Hospital,Capital Medical University,Beijing 100045,China)
出处 《儿科药学杂志》 CAS 2023年第8期24-27,共4页 Journal of Pediatric Pharmacy
关键词 磷酸肌酸钠 儿科 合理用药 creatine phosphate sodium pediatrics rational drug use
  • 相关文献

参考文献11

二级参考文献126

  • 1张伟,杨康,廖克龙,王明荣,曾会昌.肌钙蛋白对心肌损伤的评估价值[J].中国临床康复,2004,8(33):7412-7413. 被引量:4
  • 2陈永红,张玉萍,陶鹏辉,余德玲.三种心肌损伤标志物对急性心肌梗死的诊断效率评价[J].国际检验医学杂志,2007,28(4):334-336. 被引量:21
  • 3Cvetkovi'c RS,Scott LJ.Dexrazoxane:a review of its use for cardioprotection during anthracycline chemotherapy[J].Drugs,2005,65(7):1005-1024.
  • 4Barry E,Alvarez JA,Scully RE,et al.Anthracycline-induced cardiotoxicity:course,pathophysiology,prevention and management[J].Expert Opin Pharmacother,2007,8 (8):1039-1058.
  • 5Lipshultz SE,Lipsitz SR,Sallan SE,et al.Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia[J].J Clin Oncol,2005,23(12):2629-2636.
  • 6Lipshultz SE,Colan SD,Gelber RD,et al.Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood[J].N EnglJ Med,1991,324(12):808-815.
  • 7Von Hoff DD,Layard MW,Basa P,et al.Risk factors for doxorubicin-induced congestive heart failure[J].Ann Intern Med,1979,91(5):710-717.
  • 8Swain SM,Whaley FS,Ewer MS,et al.Congestive heart failure in patients treated with doxorubicin:a retrospective analysis of three trials[J].Cancer,2003,97 (11):2869-2879.
  • 9Keefe DL.Anthracycline-induced cardiomyopathy[J].Semin Oncol,2001,28(4 Suppl 12):2-7.
  • 10Ganame J,Claus P,Uyttebroeck A,et al.Myocardial dysfunction late after low-dose anthracycline treatment in asymptomatic pediatric patients[J].J Am Soc Echocardiogr,2007,20 (12):1351-1358.

共引文献320

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部